title: Antimicrobial resistance in gram-negative hospital isolates: results of the Turkish HITIT-2 Surveillance Study of 2007.
abstract: Resistance rates to amikacin, ciprofloxacin, ceftazidime, cefepime, imipenem, cefoperazone/sulbactam and piperacillin/tazobactam in Escherichia coli (n= 438), Klebsiella pneumoniae (n= 444), Pseudomonas aeruginosa (n= 210) and Acinetobacter baumanni (n=200) were determined with e-test in a multicenter surveillance study (Hitit-2) in 2007. ESBL production in Escherichia coli and K. pneumoniae was investigated following the CLSI guidelines. Overall 42.0% of E.coli and 41.4% of K. pneumoniae were ESBL producers. In E. coli , resistance to imipenem was not observed, resistance to ciprofloxacin and amikacin was 58.0% and 5.5% respectively. In K. pneumoniae resistance to imipenem, ciprofloxacin and amikacin was 3.1%, 17.8% 12.4% respectively. In P. aeruginosa the lowest rate of resistance was observed with piperacillin/tazobactam (18.1%). A. baumanni isolates were highly resistant to all the antimicrobial agents, the lowest level of resistance was observed against cefoperazone/sulbactam (52.0%) followed by imipenem (55.5%). this study showed that resistance rates to antimicrobials are high in nosocomial isolates and show variations among the centers.
authors.affiliation: Hacettepe University, School of Medicine, Clinical Microbiology Laboartory, Ankara, Turkey.
authors.forename: D
authors.initials: D
authors.lastname: Gur
authors.forename: G
authors.initials: G
authors.lastname: Hascelik
authors.forename: N
authors.initials: N
authors.lastname: Aydin
authors.forename: M
authors.initials: M
authors.lastname: Telli
authors.forename: M
authors.initials: M
authors.lastname: Gültekin
authors.forename: D
authors.initials: D
authors.lastname: Ogülnç
authors.forename: O A
authors.initials: OA
authors.lastname: Arikan
authors.forename: S
authors.initials: S
authors.lastname: Uysal
authors.forename: A
authors.initials: A
authors.lastname: Yaman
authors.forename: F
authors.initials: F
authors.lastname: Kibar
authors.forename: Z
authors.initials: Z
authors.lastname: Gülay
authors.forename: B
authors.initials: B
authors.lastname: Sumerkan
authors.forename: D
authors.initials: D
authors.lastname: Esel
authors.forename: C B
authors.initials: CB
authors.lastname: Kayacan
authors.forename: Z
authors.initials: Z
authors.lastname: Aktas
authors.forename: G
authors.initials: G
authors.lastname: Soyletir
authors.forename: G
authors.initials: G
authors.lastname: Altinkanat
authors.forename: B
authors.initials: B
authors.lastname: Durupinar
authors.forename: O
authors.initials: O
authors.lastname: Darka
authors.forename: Y
authors.initials: Y
authors.lastname: Akgün
authors.forename: B
authors.initials: B
authors.lastname: Yayla
authors.forename: S
authors.initials: S
authors.lastname: Gedikoglu
authors.forename: M
authors.initials: M
authors.lastname: Sinirtas
authors.forename: M
authors.initials: M
authors.lastname: Berktas
authors.forename: G
authors.initials: G
authors.lastname: Yaman
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D016905:Gram-Negative Bacterial Infections / Q000453:epidemiology / Q000382:microbiology*; D006801:Humans; D007362:Intensive Care Units; D008826:Microbial Sensitivity Tests; D011159:Population Surveillance; D014421:Turkey / Q000453:epidemiology; D001618:beta-Lactamases / Q000378:metabolism
chemical_list: D000890:Anti-Infective Agents; D001618:beta-Lactamases